Pfizer has launched mid-to-late-stage trials on a new oral antiviral drug that could prevent COVID-19.
The trials will test over 26-hundred adults who are living with a symptomatic coronavirus patient.
They'll will also get a small dose of Ritonavir, an antiviral drug designed to treat HIV, along with a dose of the COVID-19 candidate drug.
One third will be given placebos.
Pfizer is also working on an oral treatment for COVID-19.
The results of that study are due later this year.